SGS Life Sciences Services Becomes a Medidata Raver Accredited Partner
SGS Life Science Services's Biometrics group, one of the largest European data management, statistics and medical writing teams, became a Medidata Rave accredited partner. Medidata Rave is the industry-leading system for capturing, managing and reporting clinical research data, designed to help life science companies optimize their research investments, by efficiently streamlining the clinical trial process.
Medidata’s accreditation programme for Rave is an in-depth qualification programme through both build and process enablement tracks, with the aim for partners to provide end-user training, user and site administration, study build, reporting, outputs and migration services. Implementing Rave studies since 2010, and a Medidata CTMS partner for more than 5 years, SGS Life Science Services has robust and fully optimised processes in place, allowing for short set-up timelines that support the clinical team’s challenge of getting First Patient In (FPI) on time.
“Medidata Rave provides unmatched capabilities for complex designs that we manage in today’s oncology and infectious disease programmes, as well as when implementing targeted SDV,” explained Luc Braeken, Business Unit Manager Biometrics & Medical Affairs, SGS Life Science Services. “We find that our sponsors benefit greatly from data collection in Medidata Rave, with efficient data conversion to CDISC SDTM compliant datasets at the SGS Data Management center. Our goal is to empower our clients with full visibility on the study data at any moment via the eCRF, progress reports indicating the cleaning status and the CDISC SDTM datasets, which can be delivered soon after FPI.”
“Medidata Rave is a well-known system by many sites, allowing immediate data entry from FPI onwards without the hurdles and learning curve that are typically experienced with less-known EDC systems,” said Joris De Bondt, Head EDC and Data Standards, Medidata. “As a Medidata Rave accredited partner, SGS Life Science Services can offer the best, most innovative technology for clinical trials with a superior site experience. Our eCRF designers now have access to configurable work flows, sophisticated eCRF design, simple and complex edit checking and straight-forward integrations for a wide variety of data sources.”
Steve Heath, Medidata’s Head of Channel Sales, added: “Medidata’s industry-leading cloud platform of innovative technology and data analytics is transforming clinical development today — helping make clinical trials more cost effective, faster and safer. Our accreditation process assures life science companies are working with service partners that are fully equipped to use Medidata technology for optimal trial performance.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.